Speclipse

About:

Speclipse is a laser-based medical diagnostic technology.

Top Investors: TIPS Program, SBVA, BNH, MiCo, Shinhan Capital

Description:

Speclipse is a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms.

Total Funding Amount:

$10.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seongnam, Kyonggi-do, South Korea

Founded Date:

2015-01-01

Contact Email:

ceo(AT)speclipse.com

Founders:

Sung Hyun Pyun, Wanki Min

Number of Employees:

1-10

Last Funding Date:

2021-08-19

IPO Status:

Private

Industries: